MENU
+Compare
AIM
Stock ticker: ASE
AS OF
Jan 17, 04:59 PM (EDT)
Price
$0.21
Change
+$0.01 (+5.00%)
Capitalization
13.64M

AIM AIM ImmunoTech Forecast, Technical & Fundamental Analysis

a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders

Industry Biotechnology
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for AIM with price predictions
Jan 14, 2025

AIM's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for AIM moved out of overbought territory on January 07, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AIM as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AIM turned negative on January 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

AIM moved below its 50-day moving average on January 08, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AIM broke above its upper Bollinger Band on January 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AIM entered a downward trend on January 03, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AIM advanced for three days, in of 209 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.682) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). AIM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (58.824) is also within normal values, averaging (263.573).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

AIM is expected to report earnings to rise 100.00% to -11 cents per share on April 07

AIM ImmunoTech AIM Stock Earnings Reports
Q4'24
Est.
$-0.12
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.09
Q1'24
Est.
$-0.12
Q4'23
Missed
by $0.14
The last earnings report on November 19 showed earnings per share of -5 cents, beating the estimate of -8 cents. With 925.53K shares outstanding, the current market capitalization sits at 13.64M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2117 SW Highway 484
Phone
+1 352 448-7797
Employees
28
Web
https://www.aimimmuno.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

AIM and Stocks

Correlation & Price change

A.I.dvisor tells us that AIM and SLN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AIM and SLN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIM
1D Price
Change %
AIM100%
+8.42%
SLN - AIM
32%
Poorly correlated
+1.79%
ATAI - AIM
26%
Poorly correlated
+5.04%
ELVN - AIM
24%
Poorly correlated
-2.36%
ENTBF - AIM
23%
Poorly correlated
N/A
MNPR - AIM
23%
Poorly correlated
-6.36%
More